Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Nepafenac Once Daily for Macular Edema - Study 1

NCT01853072
completedphase_3

Nepafenac Once Daily for Macular Edema - Study 2

NCT01872611
completedphase_2

Nepafenac 0.3% Two Study

NCT01318499
completedphase_3

Confirmatory Study Nepafenac 0.3%

NCT01109173

Clinical Trials (4)

Showing 4 of 4 trials
NCT01853072Phase 3

Nepafenac Once Daily for Macular Edema - Study 1

Completed
NCT01872611Phase 3

Nepafenac Once Daily for Macular Edema - Study 2

Completed
NCT01318499Phase 2

Nepafenac 0.3% Two Study

Completed
NCT01109173Phase 3

Confirmatory Study Nepafenac 0.3%

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4